LivaNova PLC (LIVN) Market Cap & Valuation Ratios
LivaNova PLC (LIVN) has a market cap of $4.5B, a trailing P/E of 23.9 and a price-to-sales ratio of 3.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LIVNLivaNova PLCFollow LIVN — free
—
Price chart with a free account
- Market cap
- 4.5B
- P/E TTM
- 23.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LIVN | 4.5 | 23.9 | 2.9 | 17.6 | 3.3% | +12% | 13% | 14% |
| BIO | 9.9 | — | 3.7 | 42.7 | 3.6% | +1% | 2% | 0.4% |
| BRKR | 8.8 | — | 3.0 | 52.2 | 1.1% | +2% | -0.9% | -0.7% |
| HAE | 5.4 | 57.3 | 4.7 | 23.5 | 5.4% | +0.4% | 12% | 7% |
| ITGR | 4.3 | 34.7 | 3.0 | 17.4 | 2.6% | +3% | 10% | 6% |
| IRTC | 4.0 | — | 4.9 | — | 1.0% | +26% | -3% | -5% |
| NEOG | 2.7 | — | 3.7 | 30.0 | 1.9% | -0.3% | -0.8% | -0.8% |
| TMDX | 2.5 | — | 3.7 | 21.0 | 3.2% | +26% | 12% | 13% |
| UFPT | 2.3 | 31.9 | 3.8 | 20.7 | 2.7% | +7% | 15% | 14% |
| INSP | 2.1 | — | 1.9 | 24.3 | 5.7% | +4% | 6% | 7% |
| AXGN | 2.0 | — | 7.7 | — | 0.4% | +24% | -5% | -9% |
| Median of these 10 | 34.7 | 3.7 | 23.9 | 2.6% | +4% | 4% | 3% |
P/E 23.9 vs. a peer median of 34.7; EV/Sales 2.9 vs. 3.7.
Growth vs. price
each dot a company · hover or tap for valuesBIO and BRKR and IRTC and NEOG and TMDX and INSP and AXGN have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
LivaNova PLC — questions
- What is LivaNova PLC's market cap?
- $4.5B.
- What is LivaNova PLC's P/E ratio?
- 23.9 on trailing twelve-month earnings to 2026-06-30.
- What is LivaNova PLC's price-to-sales ratio?
- 3.0.
Every figure on this page comes from LivaNova PLC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.